From Sample to Insight

QIAGEN shareholders approve all agenda items related to acquisition by Thermo Fisher Scientific at Annual General Meeting

QIAGEN provides information on potential capital gain from its minority investment in ArcherDX

QIAGEN announces plans to release preliminary Q2 2020 results

QIAGEN builds on leading position in Precision Medicine with novel solutions in oncology

QIAGEN announces publication of Reasoned Position Statement for proposed acquisition by Thermo Fisher and date for Annual General Meeting

QIAGEN reports full results for first quarter of 2020

QIAGEN posts IFRS Annual Report for 2019 results and 2019 Annual Report on its website

QIAGEN N.V. to Report First Quarter 2020 Results

QIAGEN launches therascreen BRAF test as companion diagnostic to a BRAFTOVI® (encorafenib) based regimen in metastatic colorectal cancer

QIAGEN announces preliminary Q1 2020 results